Other/Press Release·FDA Press Announcements

FDA Expands Sunscreen Options for the First Time in 20 Years

HighPublished Jun 9, 2026· AI-analyzed Jun 9, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA has added bemotrizinol to the list of permitted sunscreen active ingredients, the first such expansion in approximately 20 years.

Who it affects

This update affects manufacturers of sunscreen products, regulatory professionals overseeing over-the-counter (OTC) drug compliance, and formulation scientists in the personal care sector.

Why it matters

The inclusion of a new active ingredient suggests a shift in the regulatory landscape for sunscreens, which has seen little change in permitted UV filters for decades. For regulatory teams, this likely necessitates a review of existing product portfolios and future submission strategies to incorporate bemotrizinol. This development may imply an opening for further innovation in a category that has historically faced rigid ingredient limitations.

Practical takeaway

Regulatory teams should evaluate the technical specifications for bemotrizinol inclusion in upcoming OTC monographs or filings. R&D departments should assess formulation compatibility with this newly permitted active ingredient. Compliance officers should monitor for updated labeling requirements associated with its use.

FDA source material

Today, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency's efforts to advance sunscreen innovation.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.